Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tae Heum Jeong Insider Profile
4 Followers
Tae Heum Jeong, CFO at Ocuphire Pharma, holds 505.00K shares in Ocuphire Pharma (Ticker: OCUP), holds ― shares in NeuroBo Pharmaceuticals (Ticker: NRBO), holds ― shares in Clene (Ticker: CLNN).
Tae Heum Jeong has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Tae Heum Jeong holds in companies
Most Profitable Insider Trade
The most profitable trade made by Tae Heum Jeong
Tae Heum Jeong's Trading History
Ocuphire Pharma
Jan 12, 2015
CFO
Uninformative Sell
287.93K
$1.04M
NeuroBo Pharmaceuticals
―
Director
―
―
Clene
―
Chief Finance Officer
―
―
List of latest transactions for each holding click on a transaction to see Tae Heum Jeong's performance on stock
You May Also Like
Tae Heum Jeong insider profile FAQ
What is the percentage of profitable transactions made by Tae Heum Jeong?
The percentage of profitable transactions made by Tae Heum Jeong is ―.
What is the average return per transaction made by Tae Heum Jeong?
The average return per transaction made by Tae Heum Jeong is ―.
What stocks does Tae Heum Jeong hold?
Tae Heum Jeong holds: OCUP, NRBO, CLNN stocks.
What was Tae Heum Jeong’s latest transaction?
Tae Heum Jeong latest transaction was an Uninformative Sell of $287.93K.
What was Tae Heum Jeong's most profitable transaction?
Tae Heum Jeong’s most profitable transaction was an Informative Sell of OCUP stock on September 11, 2013. The return on the trade was -61.40%.
What is Tae Heum Jeong's role in Ocuphire Pharma?
Tae Heum Jeong's role in Ocuphire Pharma is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.